我国结核病防控进入“精准化”新阶段 仁度生物TB-RNA检测技术迎来发展机遇

Core Viewpoint - The recent revision of the Infectious Disease Prevention Law in China emphasizes the need for standardized isolation treatment for infectious tuberculosis (TB) patients, marking a significant shift towards a modernized prevention and control system in TB management starting from September 1, 2025 [1][2][3]. Group 1: Policy Changes - The new law mandates standardized isolation treatment for infectious TB patients and screening of close contacts, providing a legal basis for medical institutions to implement these measures [2][3]. - The National TB Prevention and Control Plan (2024-2030) and the Guangxi TB Prevention and Control Plan (2025-2030) highlight the importance of reducing transmission in community and hospital settings through effective isolation [2][3]. Group 2: Technological Advancements - The TB-RNA nucleic acid testing system launched by Rendu Biotech is the only rapid live bacteria detection product in China, enhancing the scientific and efficient isolation treatment of infectious TB patients [1][4]. - TB-RNA technology offers unique advantages in accurately identifying live bacteria, which is crucial for controlling transmission and adjusting treatment plans, overcoming limitations of traditional methods [4][5]. Group 3: Efficiency and Economic Benefits - TB-RNA testing significantly reduces the time required for diagnosis, with results available in hours compared to weeks for traditional culture methods, thus shortening patient isolation periods and improving resource utilization [5][6]. - The integration of TB-RNA technology into diagnostic protocols is expected to yield positive health economic benefits by reducing hospitalization days and minimizing unnecessary isolation due to false positives from DNA testing [7].